BACKGROUND: The incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) among human immunodeficiency virus (HIV)-infected individuals declined after the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, but the cancer risk associated with HIV infection during the HAART era remains to be clarified. METHODS: Cancer incidence among HIV-infected and HIV-uninfected participants in the Multicenter AIDS (acquired immunodeficiency syndrome) Cohort Study (MACS) between 1984 and 2007 was compared with the expected incidence using US population-based data from the Surveillance, Epidemiology, and End Results (SEER) program. Age- and race-adjusted cancer incidence rates were also compared HIV by status and over time within the MACS. Exact statistical methods were used for all analyses. RESULTS: A total of 933 incident cancers were observed during 77,320 person-years of follow-up. Compared with SEER, MACS HIV-infected men had significantly (P<.05) elevated rates of KS (standardized incidence ratio [SIR], 139.10), NHL (SIR, 36.80), Hodgkin lymphoma (HL)(SIR, 7.30), and anal cancer (SIR, 25.71). Within MACS, HIV infection was found to be independently associated with each of these cancers across the entire follow-up period, and KS (incidence rate ratio [IRR], 54.93), NHL (IRR, 11.18), and anal cancer (IRR, 18.50) were each found to be significantly elevated among HIV-infected men during the HAART era. Among these men, the incidence of KS and NHL declined (IRR, 0.13 and 0.23, respectively), the incidence of anal cancer increased (IRR, 5.84), and the incidence of HL remained statistically unchanged (IRR, 0.75) from the pre-HAART to the HAART era. CONCLUSIONS: Cancer risk remains elevated among HIV-infected men who have sex with men, highlighting the continuing need for appropriate cancer screening in this population.
BACKGROUND: The incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) among humanimmunodeficiency virus (HIV)-infected individuals declined after the introduction of highly active antiretroviral therapy (HAART) in the mid-1990s, but the cancer risk associated with HIV infection during the HAART era remains to be clarified. METHODS:Cancer incidence among HIV-infected and HIV-uninfectedparticipants in the Multicenter AIDS (acquired immunodeficiency syndrome) Cohort Study (MACS) between 1984 and 2007 was compared with the expected incidence using US population-based data from the Surveillance, Epidemiology, and End Results (SEER) program. Age- and race-adjusted cancer incidence rates were also compared HIV by status and over time within the MACS. Exact statistical methods were used for all analyses. RESULTS: A total of 933 incident cancers were observed during 77,320 person-years of follow-up. Compared with SEER, MACSHIV-infectedmen had significantly (P<.05) elevated rates of KS (standardized incidence ratio [SIR], 139.10), NHL (SIR, 36.80), Hodgkin lymphoma (HL)(SIR, 7.30), and anal cancer (SIR, 25.71). Within MACS, HIV infection was found to be independently associated with each of these cancers across the entire follow-up period, and KS (incidence rate ratio [IRR], 54.93), NHL (IRR, 11.18), and anal cancer (IRR, 18.50) were each found to be significantly elevated among HIV-infectedmen during the HAART era. Among these men, the incidence of KS and NHL declined (IRR, 0.13 and 0.23, respectively), the incidence of anal cancer increased (IRR, 5.84), and the incidence of HL remained statistically unchanged (IRR, 0.75) from the pre-HAART to the HAART era. CONCLUSIONS:Cancer risk remains elevated among HIV-infectedmen who have sex with men, highlighting the continuing need for appropriate cancer screening in this population.
Authors: Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Gypsyamber D'Souza; Dorothy J Wiley; Xiuhong Li; Joan S Chmiel; Joseph B Margolick; Ross D Cranston; Lisa P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: Gregory D Kirk; Christian Merlo; Peter O' Driscoll; Shruti H Mehta; Noya Galai; David Vlahov; Jonathan Samet; Eric A Engels Journal: Clin Infect Dis Date: 2007-05-22 Impact factor: 9.079
Authors: Thomas Powles; David Robinson; Justin Stebbing; Jonathan Shamash; Mark Nelson; Brian Gazzard; Sundhiya Mandelia; Henrik Møller; Mark Bower Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Halie K Miller; Loredana Santo; M Constanza Camargo; Cheryl A Winkler; James J Goedert; Gilbert J Kersh; Charles S Rabkin Journal: Blood Date: 2017-04-10 Impact factor: 22.113
Authors: Kelsey L Corrigan; Leticia Nogueira; K Robin Yabroff; Chun Chieh Lin; Xuesong Han; Junzo P Chino; Anna E Coghill; Meredith Shiels; Ahmedin Jemal; Gita Suneja Journal: Cancer Date: 2019-11-11 Impact factor: 6.860
Authors: K Petoumenos; M T van Leuwen; C M Vajdic; I Woolley; J Chuah; D J Templeton; A E Grulich; M G Law Journal: HIV Med Date: 2012-08-30 Impact factor: 3.180
Authors: Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza Journal: Clin Cancer Res Date: 2015-09-17 Impact factor: 12.531